Latest Exagen Diagnostics Inc. Stories

ALBUQUERQUE, N.M., Oct. 25, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists, announced today that it has received approval to offer its patent-protected Avise SLE diagnostic, SLE-Systemic Lupus Erythematosus, in New York. This certification means that the Avise SLE brand is now available to help lupus and connective tissue disease patients nationwide. Lupus...

ALBUQUERQUE, N.M., Sept. 10, 2012 /PRNewswire/ -- Exagen Diagnostics, a commercial-stage specialty diagnostic company, today announced that it has executed a capital raise of $5.3 million led by Tullis Health Investors. Other investors include Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners and Epic Ventures. The proceeds will be used to finance market expansion and fund development of near-term pipeline products. "We are committed to the...

ALBUQUERQUE, N.M., Jan. 9, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the launch of Avise SLE, which aids in the diagnosis of lupus (Systemic Lupus Erythematosus). Avise SLE is a 5-marker panel designed to Rule-In SLE and Rule-Out other rheumatic diseases to help establish the most accurate SLE...

ALBUQUERQUE, N.M., Aug. 10, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the appointment of Eric Tornoe as President and Chief Operating Officer. Tornoe has more than 20 years of healthcare industry experience in sales, sales management and marketing, making him a key hire as Exagen broadens its test menu and moves to the...

FRANKLIN LAKES, N.J., and ALBUQUERQUE, N.M., May 23, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, and Medco Research Institute, LLC -- a wholly-owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) -- announced today they have started a joint pilot program called NIMBLE [Novel Interventions in Methotrexate Boosts Levels of Effectiveness] designed to help physicians optimize the effectiveness...

ALBUQUERQUE, N.M., Jan. 25, 2011 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, announced today the completion of the company's office expansion at the University of New Mexico Science and Technology Park. The expansion, which includes new space for both offices and a laboratory, allows Exagen to accommodate growing test volume for its gastroenterology products and the transition of the company's newly...

ALBUQUERQUE, N.M., Dec. 21, 2010 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, today announced that it has been awarded $400,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. Proceeds from the grants will be used to advance the development of biomarker studies underway, one...

ALBUQUERQUE, N.M., Oct. 12 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced the purchase of Cypress Bioscience, Inc.'s diagnostic business, located in San Diego, Calif. Under the terms of the agreement, Exagen will purchase the diagnostic business in its entirety, including all testing services, intellectual property rights and equipment. Exagen has offered employment to all Cypress...

ALBUQUERQUE, N.M., July 8 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP). The CAP is a leading organization of board-certified pathologists that serves patients, pathologists and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine. The CAP...

ALBUQUERQUE, N.M., Feb. 16 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States. Under the agreement, EndoChoice's experienced, gastroenterology-focused sales force will introduce Exagen's proprietary gene expression tests for the...